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1. Phosphorylation of Akt downstream substrates in 
response to RA treatment 
Retinoic acid (RA), the active form of vitamin A, induces neuroblastoma cells SH-SY5Y to differentiate. In addition to its classical transcriptional actions regulating 
the expression of specific genes, RA acts in an extra-genomic way, modulating the activity of relevant signalling cascades. In particular, RA treatment activates 
PI3K/Akt signalling pathway, and this activation is an essential requirement for neural differentiation (López-Carballo G. et al., J. Biol. Chem. 277, 25297-25304, 
2002). Western blots using an antibody which specifically recognizes the phosphorylation site of Akt have demonstrated that Akt activation in response to RA 
treatment produced a rapid phosphorylation of downstream substrates. Moreover, RA treatment resulted in rapid phosphorylation of well-known targets of Akt, such 
as mTOR and the ribosomal kinase p70S6, and other proteins, as CREB and histone H3, which are likely targets of RA non-genomic actions according to the 
scientific literature. We have carried out a proteomic approach in order to identify novel nuclear proteins whose phosphorylation state is modified by these extra-
genomic actions of RA. Nuclei from control and RA-treated (1mM, 30 min) neuroblastoma cells were obtained, and nuclear phospho-proteins were purified by 
affinity chromatrography. The phosph-oproteins were separated by 2-D gel electrophoresis (IEF/SDS-PAGE), and comparison of 2-D protein patterns using a 
bioinformatic software package allowed the selection of a series of spots that have undergone changes on their phosphorylation state. These spots with differential 
expression could be identified by mass spectrometry analysis as the proteins nucleophosmin/B23, hnRNP-C1/C2, hnRNP-K, HMGB1, PABP and histone H1.5. All 
those proteins have a nuclear distribution and phosphorylation sites. Finally, the observed RA-induced phosphorylation changes in these proteins were confirmed 
in 2-D western blots and immunoprecipitation experiments. 
2. Proteomic strategy to identify changes in 
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Akt activation in response to a short-time RA treatment 
produces a rapid phosphorylation of downstream 
substrates, as it is shown in western-blots using an 
antibody that specifically recognizes the Akt 
phosphorylation domain. In nuclear extracts (Fig. 1A), an 
increase of phosphorylation was detected in a double 
band of approximately 32,5 KDa, and in other around 62 
KDa. Similarly, we have performed a two-dimensional 
western blot with nuclear extracts (Fig. 1B) to identify 
the individual proteins spots that increased its 
phosphorylation as a consequence of RA treatment 
during 30 minutes. 
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RA treatment also results in rapid phosphorylation of 
well-known targets of Akt, such as mTOR and the 
ribosomal kinase p70S6 (Fig. 1C). Phosphorylation of 
mTOR and p70S6 kinase was detected after 10 minutes 
of treatment. In addition, the phosphorylation did not 
occur in the presence of LY294002 (LY), a PI3K inhibitor, 
demonstrating its dependence from Akt activation.  
The phosphorylation of Akt was not inhibited by the 
MAPKK inhibitor PD98059, neither by the MEK inhibitor 
U0126. In contrast, the PI3K/Akt pathway appears to be a 
negative regulator of ERK1,2 phosphorylation, because 
blocking PI3K with LY resulted in enhanced ERK1,2 
phosphorylation (Fig. 1D). Therefore, these results 
suggest that Akt and ERK are activated by RA in an 
independent way 
We have also considered the phosphorylation of proteins 
which are likely targets of RA non-genomic actions 
according to the scientific literature, such as CREB (Fig. 
1E) and histone H3 (Fig. 1F). CREB was rapidly 
phosphorylated in presence of RA; and Ser10 of H3, 
whose phosphorylation is associated with transcriptional 
regulation, was clearly phosphorylated only 5 minutes 
after RA treatment. Both phosphorylations showed a 
biphasic profile typical of kinase signalling.  
Comparison of two-dimensional protein 
patterns from nuclear fractions 
previously enriched in phospho-
proteins (outlined in Fig. 2A), allowed 
the selection of several spots that were 
differentially represented (Fig. 2B). 
These spots were extracted and 
identified by mass spectrometry 
analysis. A quantitative analysis of the 
differentially phosphorylated proteins, 
and a summary table of mass 
spectrometry results are shown in Fig 
2C and D. Spots 1 to 8 were over-
expressed, spot 9 was under-expressed 
and spot 10 underwent a horizontal 
displacement. All of them have a 
nuclear distribution and known 
phosphorylation sites.  
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3. Validation of the methodology by 2D western blots and immunoprecipitations of hnRNP-C1/C2 and K 
To validate our methodology, first we compared the amounts of 
some of the identified proteins in the phosphoprotein-enriched 
fractions from RA-treated and control cells (Fig. 3A). All the 
proteins tested, HMGB1, nucleophosmin and hnRNP-K, showed 
an increment in the RA-treated eluate, with the exception of 
hnRNP-C1/C2. Next, we performed two-dimensional western 
blots in pH 4-7 IPG strips with hnRNP-C1/C2 and hnRNP-K 
antibodies. A displacement of the spots towards more acidic 
forms (and, therefore, theoretically more phosphorylated) could 
be observed in RA-treated cells. Phosphorylation of hnRNP-K 
(Fig. 3B), appeared to have different kinetic profile than that of 
hnRNP-C1/C2 (Fig. 3C). Phosphorylation of hnRNP-C1/C2 could 
be detected after 10 min. RA treatment but was partially 
reversed after 30 min. These results were confirmed by 
immunoprecipitation/Western Blot experiments with specific 
antibodies for phosphorylated amino acids. Both HnRNP-C1/C2 
(Fig. 3D) as well as hnRNP-K (Fig. 3E) IPs revealed a 
phosphorylation increase in serine but not in tyrosine as a 
consequence of RA treatment.  
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1 Nucleophosmin MSVQPTVSLGGFEITPPVVLR 
DELHIVEAEAMNYEGSPIK 
45,1 
4x10-5 
13,6 % 29-32 4,5 
2 y 10 Histone H1.5 KATGPPVSELITK 
ERNGLSLAALK 
ALAAGGYDVEKNNSR 
SLVSKGTLVQTK 
GTGASGSFKLNK 
KAASGEAKPK 
AKKPAGATPK 
KPAAAGVKK 
316 
5x10-14 
41 % 22 10,9 
3 y 4 HMGB1 GKMSSYAFFVQTCR 
KHPDASVNFSEFSK 
GKFEDMAK 
TYIPPKGETK 
FKDPNAPK 
RPPSAFFLFCSEYRPK 
IKGEHPGLSIGDVAK 
KLGEMWNNTAADDKQPYEK 
YEKDIAAYRKEEEEDEEDEED
EEEEEDEEDEDEEEDDDDE 
368 
2x10-53 
67 % 25 6,5 
6 y 7 HnRNP-C1/C2 MIAGQVLDINLAAEPK 
GFAFVQYVNER 
34,3 
0,062 
8,8 % 39-41 4,95 
8 HnRNP-K NLPLPPPPPPR 
ILSISADIETIGEILKK 
IILDLISESPIK 
39,3 
0,002 
7,1 % 65 5,4 
9 PABP2 GFAYIEFSDKESVR 
TSLALDESLFR 
51,6 
4x10-7 
5,7 % 50 5,2 
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